Worldwide Clinical Trials to Lead Roundtable Discussion on Retention & Faster Access to Patients at World Orphan Drug Congress

Worldwide's Chief Medical & Scientific Officer, Dr. Michael Murphy, to moderate panel of industry leaders

07 Apr, 2016, 09:00 ET from Worldwide Clinical Trials

MORRISVILLE, North Carolina, April 7, 2016 /PRNewswire/ --

Worldwide Clinical Trials announces that Michael Murphy M.D., Ph.D., the company's Chief Medical & Scientific Officer, will lead a roundtable discussion entitled, "Retention and Faster Access to Rare Disease Patients," during the World Orphan Drug Congress (WODC) 2016, set for April 20-22 in Washington D.C. 

During the WODC roundtable discussion, which will take place on Friday, April 22 at 11:40 a.m., Dr. Murphy will draw upon his more than 25 years of expertise and the international experience of Worldwide Clinical Trials in the design and execution of clinical programs within the orphan disease space. Discussion topics will include optimal study team dynamics, the impact of evolving regulatory guidance and evidentiary standards on patient access, expanded access programs that can facilitate registration and commercialization, participatory research models, and advocacy group involvement.   

"The number of rare disease clinical development programs conducted each year is on the rise, while at the same time we are faced with patient access and retention challenges that are inherent to these trials," commented Dr. Murphy. "During our roundtable discussion, we'll be speaking with leading experts about how we can best optimize program design and execution to enable patient access, facilitate participation and promote patient and family engagement - all with the goal of speeding the discovery of treatments for those patients affected by rare diseases."   

Worldwide Clinical Trials, which will showcase its services at WODC at booth #23, has participated in the design, execution and analysis of more than 50 studies in orphan diseases. Therapies have included novel chemical and biological entities, as well as repurposed products, addressing symptomatic or disease modification hypotheses across a range of therapeutic areas. 

For more information about WODC, please visit http://www.terrapinn.com/conference/world-orphan-drug-congress-usa/. To learn more about Worldwide Clinical Trials, please visit http://www.Worldwide.com .  

Connect with Worldwide Clinical Trials:  

About Worldwide Clinical Trials  

Worldwide Clinical Trials employs more than 1,400 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. One of the world's leading, full-service contract research organizations (CROs), we partner with sponsors in the pharmaceutical and biotechnology industries to deliver fully integrated clinical development and bioanalytical services, extending from first-in-human through phase IV studies. Grounded in medicine and science, we help sponsors move from medical discovery into clinical development and commercialization across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID), and rare diseases. For more information, visit http://www.Worldwide.com.

SOURCE Worldwide Clinical Trials